Home Biosimilar Antibodies Others Others Ladiratuzumab (Anti-LIV-1 / SLC39A6)
For research use only. Not for use in humans.

Ladiratuzumab (Anti-LIV-1 / SLC39A6)

Synonyms: ZIP6， SLC39A6

Ladiratuzumab (Anti-LIV-1 / SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. MW: 145.5 kD.

Ladiratuzumab (Anti-LIV-1 / SLC39A6)

Quality Control

Batch: A240902 Purity: 99% Protein concentration: 7.11mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Ladiratuzumab (Anti-LIV-1 / SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. MW: 145.5 kD.

Product Details

CAS No. 1629760-28-6
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03310957 COMPLETED Drug: ladiratuzumab vedotin|Drug: Pembrolizumab Triple Negative Breast Neoplasms Seagen Inc. 2018-02-27 PHASE1; PHASE2
NCT04032704 TERMINATED Drug: ladiratuzumab vedotin|Drug: pembrolizumab Small Cell Lung Cancer; Non-small Cell Lung Cancer, Squamous; Non-small Cell Lung Cancer, Non-squamous; Head and Neck Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Prostate Cancer; Melanoma Seagen Inc. 2019-10-09 PHASE2
NCT01969643 COMPLETED Drug: ladiratuzumab vedotin|Drug: Trastuzumab HER2 Positive Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Triple Negative Breast Neoplasms; HER2 Mutations Breast Neoplasms Seagen Inc. 2013-10-22 PHASE1

(data from https://clinicaltrials.gov, updated on 2025-12-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.